# A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

Study · id `cardio:ct-nct07619131` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07619131](<https://clinicaltrials.gov/study/NCT07619131>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07619131

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07619131. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-12 (actual); primary completion 2027-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07619131, source copy `cardio:ctgov-nct07619131-2026-09-10`, retrieved 2026-10-31)
- Started: 2026-08-12 (actual) (ClinicalTrials.gov record NCT07619131, source copy `cardio:ctgov-nct07619131-2026-09-10`, retrieved 2026-10-31)
- Primary completion: 2027-07-30 (anticipated) (ClinicalTrials.gov record NCT07619131, source copy `cardio:ctgov-nct07619131-2026-09-10`, retrieved 2026-10-31)
- Completion: 2027-07-30 (anticipated) (ClinicalTrials.gov record NCT07619131, source copy `cardio:ctgov-nct07619131-2026-09-10`, retrieved 2026-10-31)
- Countries: United States; Bulgaria; Canada; Denmark; Germany; Hungary; Israel; Poland; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT07619131, source copy `cardio:ctgov-nct07619131-2026-09-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07619131-2026-09-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
- Condition: Hypercholesterolaemia
- Intervention (Drug): Laroprovstat
- Intervention (Drug): Rosuvastatin 1
- Intervention (Drug): Rosuvastatin 2
- Intervention (Drug): Laroprovstat/Rosuvastatin 1
- Intervention (Drug): Placebo to match rosuvastatin
- Intervention (Drug): Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1
- Intervention (Drug): Laroprovstat/Rosuvastatin 2
- Intervention (Drug): Placebo to match Laroprovstat/Rosuvastatin 2
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: c7209b1953001a83af674eddae66568d341b18e6f7f1e579028b0e39b523f84f
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
